



NDA 20-742/S-008

Alcon Laboratories, Inc.
c/o Alcon Research, Ltd.
Attention: Sarah J. Cantrell
Sr. Manager, Regulatory Affairs
6201 South Freeway
Fort Worth, Texas 76134-2099

Dear Ms. Cantrell:

Please refer to your supplemental new drug application dated March 31, 2004, received April 2, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for BSS (balanced salt solution) Sterile Irrigating Solution.

This "Changes Being Effectuated in 30 days" supplemental new drug application provides for labeling changes to the 15 mL and 30 mL drug product sizes.

We completed our review of this supplemental new drug application. It is approved, effective on the date of this letter, for use as recommended in the final printed labeling (FPL) submitted on March 31, 2004. The text for the approved package insert and backing paper is enclosed.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

NDA 20-742/S-008

Page 2

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Lori M. Gorski, Regulatory Project Manager, at (301) 827-2090.

Sincerely,

{See appended electronic signature page}

Wiley A. Chambers, M.D.
Deputy Director
Division of Anti-Inflammatory, Analgesic
and Ophthalmic Drug Products, HFD-550
Office of Drug Evaluation V
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Wiley Chambers
9/30/04 04:03:53 PM